Compare Ascendis Pharma A/S (ASND) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Thomson Reuters Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Thomson Reuters Corp trades at $89.65 (market cap $38.95B). The key difference: Thomson Reuters Corp is far larger — about 2.2× Ascendis Pharma A/S's market cap, and Thomson Reuters Corp pays a 2.92% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TRI | |
|---|---|---|
Market Cap | $17.74B | $38.95B |
Sector | Health | Industrials |
52-Week High | $277.18 | $214.21 |
52-Week Low | $163.32 | $76.55 |
Enterprise Value | $18.11B | $40.91B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Thomson Reuters (TRI) trades at $89.65, up 0.92% today, with a bullish technical signal and strong support at $88. The company shows robust fundamentals with a 19.93% net income margin and consistent earnings beats, though Q4 2025 missed expectations. Recent AI partnerships and a special dividend highlight strategic moves, while cash flow turned negative in 2025 due to investing activities.
Outlook is positive with a consensus price target of $129.96, implying 45% upside, supported by 51.85% analyst buy ratings. Risks include AI implementation challenges and revenue volatility, but the stock's valuation at P/E 25.8 appears reasonable given growth prospects in legal and compliance sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
